Headquartered in Konstanz (Germany), LifeCodexx AG has been developing innovative and clinically validated non-invasive diagnostic tests based on the newest molecular analytical methods since 2010. With the PrenaTest®, Europe’s first non-invasive prenatal test (NIPT) for the determination of the most common chromosomal disorders in unborn children, launched in 2012, LifeCodexx AG has been changing prenatal diagnostics considerably. The test is performed within Germany in strict conformity with the highest quality standards as per the European Directive on In-vitro Diagnostic Medical Devices.
All of our work is focused on providing expectant mothers with reliable and safe diagnostic tests that enable them to make their own decisions at an early point in their pregnancies.
We guarantee the high quality of our diagnostic tests. They meet strict German and European quality standards at all times and are developed and performed exclusively within Germany. We guarantee the protection and security of all personal data.
Our approach is shaped by exceptional compassion, respect, and esteem, especially for expectant mothers and their families, as well as for their treating physicians and the interested public. It is our desire to provide competent and transparent care at all times in accordance with each personal situation.
We draw our motivation and strength from the constructive, faithful, and long-standing collaboration with our employees, associates, and the many physicians who have chosen to offer our high-quality diagnostic tests to their patients.